DOWNSTREAM PROCESSING FEATURED ARTICLES
GE Healthcare Life Sciences Launches Capto™ L Chromatography Medium For Capture Of Antibodies And Antibody Fragments
GE Healthcare’s Capto L affinity chromatography medium (resin) is designed for the purification of antibody fragments. It combines a rigid, high-flow agarose matrix with the immunoglobulin-binding recombinant protein L ligand, which has strong affinity for the variable region of antibody’s kappa light chain.
-
Sanofi Pasteur Announces Publication In The Lancet Of World's First Efficacy Results For Its Dengue Vaccine Candidate
Sanofi Pasteur, the vaccines division of Sanofi, announced recently the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types. The results of the world’s first efficacy study confirm the excellent safety profile of Sanofi Pasteur’s dengue vaccine candidate.
-
NIH-Supported Study Shows How Immune Cells Change Wiring Of The Developing Mouse Brain
Researchers have shown in mice how immune cells in the brain target and remove unused connections between brain cells during normal development.
-
BARDA Continues Novavax' Influenza Vaccine Programs Following In-Process Review
Novavax, Inc. (Nasdaq:NVAX) today announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review (IPR) of Novavax' contract covering the company's recombinant virus-like particle (VLP) vaccine candidates for pandemic and seasonal influenza.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
![Monoclonal Antibody Purification Platform Using High-Capacity Protein A And Mixed-Mode Chromatography]( "Monoclonal Antibody Purification Platform Using High-Capacity Protein A And Mixed-Mode Chromatography")
Monoclonal Antibody Purification Platform Using High-Capacity Protein A And Mixed-Mode ChromatographyThe first step in purification of an important class of therapeutic proteins, the polyclonal or monoclonal antibodies (mAbs), is their capture from plasma or tissue culture supernatants. Protein A–based media are by far the most common class of affinity products used for this purpose.
-
Improving DNA Removal from Bioprocess Purification Processes
Many new biological drug products produced using recombinant DNA technology, such as monoclonal antibodies, are produced in cell culture. Because therapeutic proteins such as monoclonal antibodies are produced in cell culture, impurities can result from the host cells, or cell substrates. By 3M Purification Inc.
-
An Automated Profiling Application For G9a Histone Methyltransferase And Bromodomain Proteins
Due to several findings, G9a and BET bromodomain proteins have become the target for numberous drug discovery projects. In this study, we describe a novel, cell-based assay platform that uses the robust, yet simple Enzyme Fragment Complementation (EFC) Technology.
-
Agilent Microarray Grant Application Support White Paper This guide offers an overview of Agilent’s microarray and SureSelect product offerings with ordering details to assist researchers with the details of grant submission.
-
![Bio-rad]( "Improving Aggregate Removal From mAb Feed Using Cation Exchange Chromatography")
Improving Aggregate Removal From mAb Feed Using Cation Exchange ChromatographyResearchers in the field of chromatography have required ever more sophisticated and selective methods for removing aggregates from the monomer.
-
![Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media]( "Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media")
Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography MediaMonoclonal antibodies (mAbs) remain a predominant class of therapeutic protein products on the market because of their wide range of applications in disease treatment and diagnosis. Over the years, upstream technology advancements have helped improve the titer of target antibodies, from merely 1 g/L two decades ago to 10–13 g/L in fed-batch processes and up to 25 g/L in perfusion cultures today (Gronemeyer et al. 2014).
DOWNSTREAM PROCESSING PRODUCTS
Our integrated single-use bioreactors are designed as complete out-of-the-box jacketed systems, each paired with an integrated controller and temperature control unit (TCU).
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.